Life sciences company Thermo Fisher (NYSE:TMO) reported Q1 CY2026 results exceeding the market’s revenue expectations, with ...

Clinical trial tech company Clario has sealed its second acquisition in a week, doubling down further on neuroscience by picking up imaging specialist NeuroRx. NeuroRx founder and CEO Douglas Arnold, ...

XROI™ (Executive Reputation & Opportunity Index) is a proprietary framework developed by Clario Group. All scoring models, ...

PHILADELPHIA, March 17, 2025 /PRNewswire/ -- Clario, a leading provider of endpoint data solutions to the clinical trial industry, today announced they have acquired NeuroRx, a leader in imaging ...

Drug research is changing and there are opportunities for growth, says Christopher Fikry, the new CEO of clinical trial tech firm Clario. Fikry, who Clario named as its new chief last month, shared ...

Thermo Fisher’s first quarter results received a negative market reaction, despite topping Wall Street’s revenue expectations ...

Acquisition advances Clario's Respiratory Solutions portfolio, combining Clario's deep scientific expertise with ArtiQ's innovative artificial intelligence capabilities "We're thrilled to welcome ...

Clario's third annual ESG report for the calendar year 2023 highlights advancements in responsible artificial intelligence (AI), employee program investments, and ambitious science-based ...

The fusion of Clario's innovative endpoint technologies and CellCarta's sample management expertise offers a single-vendor solution for imaging and histopathology in clinical trials, advancing ...

XROI™ anchors a broader suite of AI-powered solutions designed to elevate leadership performance and organizational impact NEW YORK, April 27, 2026 /PRNewswire/ -- Clario Group today announced the ...